Entasis Therapeutics Introduces First-in-Class Candidate, ETX0462, and Presents Data on SUL-DUR and ETX0282CPDP at World Microbe Forum

WALTHAM, Mass., June 18, 2021 (GLOBE NEWSWIRE) —

Entasis Therapeutics

Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the World Microbe Forum 2021, taking place virtually June 20-24. Entasis will present 11 posters with one oral presentation highlighting ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against

Pseudomonas aeruginosa.

Presentations will also include updates on SUL-DUR, a β-lactam/β-lactamase inhibitor currently in a Phase 3 registrational clinical trial to treat infections caused by carbapenem-resistant

Acinetobacter baumannii

, and ETX0282CPDP, an oral β-lactam/β-lactamase inhibitor being developed to treat multidrug-resistant Gram-negative pathogens, including those caused by extended-spectrum β-lactamases (ESBLs) and carbapenem-resistant

Enterobacteriaceae

(CRE).

The details of the presentations are as follows:



SUL-DUR Presentations:


Poster

: Outer membrane permeability and efflux do not limit antibacterial activity of sulbactam-durlobactam in

Acinetobacter baumannii



Session:

AAR09 Pharmacological Studies of Investigational Agents Pre-NDA


Poster Number: WMF21-0322


Poster

: Effect of Susceptibility Testing Conditions on the

In Vitro

Antibacterial Activity of Sulbactam-Durlobactam


Session

: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA


Poster Number: WMF21-0325


Poster

: Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using a CLSI M23-A4 Study Design


Session

: AAR09 Pharmacological Studies of Investigational Agents Pre-NDA


Poster Number: WMF21-0326



ETX0282CPDP Presentation:


Poster

: The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017-2019), geographically diverse drug-resistant

Enterobacterales

isolates


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number: WMF21-0290



ETX0462 Presentations:


Oral Presentation

: The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR

Pseudomonas aeruginosa



Session

: AAR107 New Agents Discovery Summary Session: Early New Antimicrobial Agents


Date and Time

: Monday, June 21, 2021, 11:00am-12:30 pm


Poster

: ETX0462 Inhibits Penicillin-Binding Protein 3 of

Pseudomonas aeruginosa

and

Escherichia coli



Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0287


Poster

: ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative, Clinical Isolates


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0293


Poster

: The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Retains Potent Antibacterial Activity Across Isogenic Panels of Gram-negative Resistant Determinants


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0288


Poster

: ETX0462, a Novel Non β-lactam PBP Inhibitor, Is Bactericidal Against Gram negative pathogens with a Low Propensity for Mutant Generation


Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Poster Number

: WMF21-0286


Poster

: Evaluation of the Pharmacokinetics/Pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against

Pseudomonas aeruginosa

Infections, Including MDR Strains


Session

: AAR07 Antimicrobial Pharmacokinetics and Pharmacodynamics


Poster Number

: WMF21-0292


Poster

: The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens

In Vitro

and

In Vivo



Session

: AAR08 New Antimicrobial Agents (in vitro and in vivo Studies Prior to the Start of Clinical Therapeutic Studies/pre-Phase 2)


Date and Time

: WMF21-0312


About Entasis Therapeutics Inc.


Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting

Acinetobacter baumannii

infections), zoliflodacin (targeting

Neisseria gonorrhoeae

infections), ETX0282CPDP (targeting

Enterobacteriaceae

infections) and ETX0462 (targeting

Pseudomonas

infections). For more information, visit www.entasistx.com.


Company Contact

Investor Contact
Kyle Dow Bruce Mackle
Entasis Therapeutics LifeSci Advisors
(781) 810-0114 (929) 469-3859


[email protected]


[email protected]



Primary Logo